Arena(cultivate), Crohn’s

Arena(cultivate), Crohn’s

Title: A Study Evaluating the Efficacy and Safety of Etrasimod in the Treatment of Patients With Moderately to Severely Active Crohn’s Disease (CULTIVATE)

Associated condition: Crohn’s disease

Status: Currently enrolling

Brief summary: This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study that seeks to evaluate the efficacy and safety of oral etrasimod as induction therapy in 225 participants with moderately to severely active Crohn’s Disease. Participants in the experimental arm of the study will receive etrasimod (APD334) tablet taken orally once daily; those in the placebo arm of the study will receive a matching placebo tablet taken by mouth, once a day.

Primary objectives: To evaluate the safety and efficacy of etrasimod in subjects with moderately to severely active Crohn’s disease.

Estimated length of study: Estimated Study Completion Date of August 2021

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

HIPAA COMPLIANT FORM

Title: A Study Evaluating the Efficacy and Safety of Etrasimod in the Treatment of Patients With Moderately to Severely Active Crohn’s Disease (CULTIVATE)

Associated condition: Crohn’s disease

Status: Currently enrolling

Brief summary: This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study that seeks to evaluate the efficacy and safety of oral etrasimod as induction therapy in 225 participants with moderately to severely active Crohn’s Disease. Participants in the experimental arm of the study will receive etrasimod (APD334) tablet taken orally once daily; those in the placebo arm of the study will receive a matching placebo tablet taken by mouth, once a day.

Primary objectives: To evaluate the safety and efficacy of etrasimod in subjects with moderately to severely active Crohn’s disease.

Estimated length of study: Estimated Study Completion Date of August 2021

For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.

Submit Your Information for Consideration

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.